Hims Shares Drop 5% After FDA Flags Peptide Safety, Analyst Maintains Buy
HIMS•Hims shares fell 5% overnight after FDA staff flagged safety concerns over its popular peptides, marking its steepest one-day drop in two months. One analyst maintained a buy rating, citing low adverse event rates and robust subscription renewal metrics to offset short-term regulatory uncertainty.
1. FDA Staff Safety Queries
FDA reviewers raised questions about the safety profile of Hims’ leading peptide offerings, noting limited long-term clinical data and potential adverse effects. The staff’s concerns centered on whether existing trials adequately address real-world usage risks.
2. Stock Market Reaction
Hims shares slid 5% in overnight trading, erasing recent gains and triggering unusually high volume as investors reassessed regulatory exposure. The drop represents the largest single-day decline for the stock in roughly two months.
3. Analyst Support and Outlook
Despite the sell-off, one analyst reiterated a Buy rating, emphasizing low reported side-effect rates and strong subscription renewal trends. The analyst argued that Hims’ telehealth platform and recurring revenue model should mitigate short-term regulatory headwinds.
